A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

Although initial rituximab-containing chemotherapies achieve high response rates, indolent B-cell non-Hodgkin lymphoma (B-NHL), such as follicular lymphoma (FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Michinori, Ando, Kiyoshi, Suzuki, Tatsuya, Ishizawa, Kenichi, Oh, Sung Yong, Itoh, Kuniaki, Yamamoto, Kazuhito, Au, Wing Yan, Tien, Hwei-Fang, Matsuno, Yoshihiro, Terauchi, Takashi, Yamamoto, Keiko, Mori, Masahiko, Tanaka, Yoshinobu, Shimamoto, Takashi, Tobinai, Kensei, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282031/
https://www.ncbi.nlm.nih.gov/pubmed/24617454
http://dx.doi.org/10.1111/bjh.12819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282031/
https://www.ncbi.nlm.nih.gov/pubmed/24617454
http://dx.doi.org/10.1111/bjh.12819

Ejemplares similares